News Sentiment

PYXS sentiment intelligence

Pyxis Oncology Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 59 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.67 Week of 10 Jul 2026
Weighted tone 59/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+1.5% over one week, +51.7% over four weeks, trend active, and near fair-value range.

Latest direct headline Negative

Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction 1.5% Price digesting
Trend fit Trend active 51.7% over four weeks
Fair value 8.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 28
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 6
Moomoo 6
TradingView 6
GlobeNewswire 6
Investing.com 3
simplywall.st 3
The Globe and Mail 2

Event Lens

What the news is about

Classified themes
Market update 25
Earnings 13
Analyst action 10
Balance sheet 6
Deals and strategy 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Seeking Alpha Direct company coverage

Pyxis Oncology: The Market Might Have Already Ruled On Micvotabart Pelidotin

Pyxis Oncology is developing micvotabart pelidotin for head and neck cancer, but previous updates received a poor market reception. Concerns exist regarding competition with GMAB's petosemtamab, side effect-related discontinuations, and limited durability data. A fall 2026 update

Tone
Negative 36/100
Event
Market update
Published
14 Jul 2026 10:05
Source
Seeking Alpha
Stock Titan Direct company coverage

Biotechnology Value Fund group (NASDAQ: PYXS) reports 9.99% capped stake in Pyxis

The Biotechnology Value Fund (BVF) group and its affiliates have disclosed a near-10% beneficial ownership stake in Pyxis Oncology (NASDAQ: PYXS), primarily through warrants. As of July 10, 2026, the group held 7,840,062 warrants, exercisable at $3.289 per share, but a 9.99% bene

Tone
Neutral 50/100
Event
Deals and strategy
Published
10 Jul 2026 20:10
Source
Stock Titan
The Globe and Mail Direct company coverage

RBC Capital Reaffirms Their Buy Rating on Pyxis Oncology (PYXS)

RBC Capital analyst Leonid Timashev has reaffirmed a Buy rating on Pyxis Oncology (PYXS) with a price target of $5.00. This positive outlook is supported by similar ratings from H.C. Wainwright, despite William Blair reiterating a Hold rating. The company recently reported a GAAP

Tone
Positive 67/100
Event
Analyst action
Published
10 Jul 2026 01:40
Source
The Globe and Mail
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS) and Glaukos (GKOS)

Two healthcare companies, Pyxis Oncology (PYXS) and Glaukos (GKOS), recently received bullish sentiments from analysts. H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating for Pyxis Oncology with a $7.00 price target, while BTIG analyst Ryan Zimmerman maintaine

Tone
Positive 72/100
Event
Analyst action
Published
07 Jul 2026 19:41
Source
The Globe and Mail
Investing.com Direct company coverage

H.C. Wainwright reiterates Pyxis Oncology stock rating at buy

H.C. Wainwright has reiterated a Buy rating and a $7.00 price target for Pyxis Oncology Inc. (NASDAQ:PYXS) following updates to the company's clinical data timeline. The company has adjusted the expected release of updated data for its monotherapy MICVO study and the Phase 1/2 co

Tone
Positive 66/100
Event
Analyst action
Published
06 Jul 2026 12:11
Source
Investing.com
Moomoo Direct company coverage

Pyxis Oncology(PYXS) Stock Options Chain | Quotes & News

This article provides access to the stock options chain, quotes, and news for Pyxis Oncology (PYXS). It serves as a comprehensive resource for investors interested in the company's financial and market performance.

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 06:40
Source
Moomoo
Moomoo Direct company coverage

Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $8

Stifel has reiterated its Buy rating for Pyxis Oncology (PYXS.US) and maintained its target price of $8. This indicates the firm's continued positive outlook on the company's stock performance and valuation. The report suggests that Stifel sees significant potential in Pyxis Onco

Tone
Positive 75/100
Event
Analyst action
Published
03 Jul 2026 05:40
Source
Moomoo
TradingView Direct company coverage

Pyxis Oncology Raises $50 Million in Private Placement; Warrants Could Add ~$64 Million

Pyxis Oncology has secured approximately $50 million through a private placement of common shares and warrants. The warrants, exercisable later, could contribute an additional $64 million if fully utilized. This financing is intended to extend the company's cash runway into Q2 20

Tone
Positive 76/100
Event
Balance sheet
Published
02 Jul 2026 20:39
Source
TradingView
Stock Titan Direct company coverage

Pyxis Oncology (NASDAQ: PYXS) raises up to $114M in private placement to fund MICVO trials

Pyxis Oncology (NASDAQ: PYXS) has secured up to $114 million through a private placement to fund its MICVO trials and extend its cash runway into Q2 2027. The financing includes an upfront gross proceeds of approximately $50 million from the sale of common stock and matching warr

Tone
Positive 63/100
Event
Balance sheet
Published
02 Jul 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Pyxis Oncology (PYXS) director sells 35K shares after option exercise

Pyxis Oncology director Jakob Dupont exercised stock options for 35,000 shares at $1.60 per share and subsequently sold all 35,000 shares in open-market transactions at a weighted average price of $3.06 per share. This sale was conducted under a pre-arranged Rule 10b5-1 trading p

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:39
Source
Stock Titan
GuruFocus Direct company coverage

PYXS Maintains by Leerink Partners -- Price Target Lowered to $7

Leerink Partners has maintained an "Outperform" rating for Pyxis Oncology (PYXS) but lowered its price target from $9.00 to $7.00. This adjustment reflects a shift in outlook despite the positive rating. Pyxis Oncology, a clinical-stage oncology company, currently has a GF Score™

Tone
Negative 36/100
Event
Analyst action
Published
02 Jul 2026 15:12
Source
GuruFocus
Investing.com Direct company coverage

Leerink cuts Pyxis Oncology stock price target on valuation

Leerink has lowered its price target for Pyxis Oncology Inc. (NASDAQ:PYXS) to $7.00 from $9.00, while maintaining an Outperform rating. Despite the reduction, the new target still implies significant upside from the current stock price, and the firm remains positive on the compan

Tone
Positive 63/100
Event
Analyst action
Published
02 Jul 2026 10:12
Source
Investing.com
AllSci Direct company coverage

Pyxis Oncology Secures $114M for MICVO Cancer Trial

Pyxis Oncology has secured up to $114 million in a private placement to fund the continued development of its lead antibody-drug conjugate (ADC), micvotabart pelidotin (MICVO). This financing extends their cash runway into Q2 2027 and will support two upcoming clinical data reado

Tone
Positive 72/100
Event
Balance sheet
Published
02 Jul 2026 05:39
Source
AllSci
TradingView Direct company coverage

Pyxis Oncology, Inc. Financial Disclosures & SEC Filings

This article provides a comprehensive list of Pyxis Oncology, Inc.'s financial disclosures and SEC filings, including earnings reports, annual reports, quarterly reports, and event transcripts from various healthcare conferences. It highlights the company's clinical progress, par

Tone
Positive 73/100
Event
Earnings
Published
02 Jul 2026 01:09
Source
TradingView
TradingView Direct company coverage

Pyxis Oncology, Inc. Stock 12‑Month Price Target Raised to $7.14, Implies 137% Upside

Pyxis Oncology, Inc. (PYXS) has seen its average 12-month price target raised from $6.88 to $7.14 by analysts, with a range of $5 to $9 per share. This new target suggests a potential upside of approximately 137% based on the recent closing price. The consensus rating for PYXS re

Tone
Positive 91/100
Event
Analyst action
Published
01 Jul 2026 14:41
Source
TradingView
Legal Desire Media and Insights Direct company coverage

Latham & Watkins Advises on Pyxis Oncology’s Up to US$114 Million Private Placement Financing

Latham & Watkins LLP advised on Pyxis Oncology's private placement financing, which is expected to generate gross proceeds of approximately US$50 million, with an additional US$64 million if accompanying warrants are fully exercised. Pyxis Oncology, a clinical-stage company focus

Tone
Positive 74/100
Event
Market update
Published
01 Jul 2026 08:41
Source
Legal Desire Media and Insights
Moomoo Direct company coverage

William Blair Maintains Pyxis Oncology(PYXS.US) With Hold Rating

William Blair has reiterated its "Hold" rating for Pyxis Oncology (PYXS.US). This indicates that the firm advises investors to continue holding their shares in the company without recommending a buy or sell action at this time.

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jul 2026 04:40
Source
Moomoo
Latham & Watkins LLP Direct company coverage

Latham Advises on Pyxis Oncology Up to Private Placement Financing

Latham & Watkins LLP advised the placement agent in a private placement financing for Pyxis Oncology, Inc. The financing is expected to generate approximately US$50 million in gross proceeds, with an additional US$64 million possible if accompanying warrants are fully exercised.

Tone
Positive 72/100
Event
Market update
Published
01 Jul 2026 03:40
Source
Latham & Watkins LLP
Stock Titan Direct company coverage

[144] Pyxis Oncology, Inc. SEC Filing

This article details a Form 144 SEC filing by Pyxis Oncology, Inc. (PYXS), indicating a proposed sale of 35,000 shares of common stock with an aggregate market value of $107,033.66. The filing notes the securities were acquired on June 30, 2026, via a stock option exercise and ar

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 20:40
Source
Stock Titan
Bitget Direct company coverage

Pyxis Oncology, Inc. (PYXS) announced the completion of a private financing agreement with a total funding amount up to 114 millions dollars.

Pyxis Oncology, Inc. (PYXS) has successfully completed a private financing agreement, securing up to $114 million. This funding is specifically earmarked to advance their lead candidate drug, Micvo, through crucial clinical development stages and accelerate its progress towards k

Tone
Positive 95/100
Event
Market update
Published
30 Jun 2026 19:40
Source
Bitget
marketscreener.com Direct company coverage

Pyxis Oncology Secures Up to $114 Million Private Placement

Pyxis Oncology (NasdaqGS:PYXS) has secured up to $114 million through a private placement. The clinical

Tone
Positive 81/100
Event
Market update
Published
30 Jun 2026 14:39
Source
marketscreener.com
TradingView Direct company coverage

Pyxis Oncology Announces Up To $114 Million Private Placement Financing To Advance Micvo Through Key Clinical Milestones

Pyxis Oncology has announced a private placement financing round that could raise up to $114 million. This funding is intended to support the advancement of their drug candidate, Micvo, through critical clinical milestones. The announcement was made via Reuters and Refinitiv.

Tone
Positive 71/100
Event
Market update
Published
30 Jun 2026 12:39
Source
TradingView